0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Clinicopathologic Reports, Case Reports, and Small Case Series |

Vitreous Opacities and Retinal Vascular Abnormalities in Gaucher Disease FREE

Eric M. Shrier, DO; Charles C. Barr, MD; Gregory A. Grabowski, MD
[+] Author Affiliations

Section Editor: W. Richard Green, MD


Arch Ophthalmol. 2004;122(9):1395-1398. doi:10.1001/archopht.122.9.1395.
Text Size: A A A
Published online

Gaucher disease is an autosomal recessive lipid-storage disease. Deficiencyin the enzyme glucosylceramidase, normally present in macrophage lysosomes,leads to accumulation of glucosylceramide in scavenger macrophages and subsequentdeposition in the organs of the reticuloendothelial system (liver, spleen,and bone marrow). Enlarged macrophages with a foamy cytoplasm, likened to"crinkled tissue paper," with an eccentrically placed nucleus (Gaucher cells)are abundant, leading to organomegaly with resultant pancytopenia.1 In the past, many affected patients were treatedwith splenectomy at an early age to eliminate splenomegaly and resultant splenicsequestration of platelets. During the past decade, enzyme replacement therapywith intravenous infusions of glycosylceramidase has proven safe and effectivefor treating the visceral manifestations of Gaucher disease.2

A 20-year-old white woman had best-corrected visual acuities of 20/160OD and 20/60 OS. There was a small-angle esotropia in the right eye. Althoughshe had long complained of floaters, her visual acuity had been correctableto 20/25 OU until 2 years earlier. Results of anterior segment examinationwere normal. The posterior segment examination showed moderate to dense vitreousopacities in both eyes, overlying the optic nerve head, vessels, and vitreous(Figure 1). There was a conspicuousabsence of inflammatory cells in the vitreous bilaterally. Fluorescein angiographyshowed normal dye transit, blockage of fluorescence due to the vitreal opacities,and marked vascular tortuosity (Figure 2).

Place holder to copy figure label and caption
Figure 1.

Fundus photographs of both eyesshowing prominent vitreous opacities.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Fluorescein angiograms of botheyes in transit phase showing blockage of fluorescence caused by vitreal opacities,and vascular tortuosity.

Graphic Jump Location

The patient underwent standard 20-gauge pars plana vitrectomy in theright eye. A vitreous aspirate specimen obtained before infusion instillationwas stained with hematoxylin-eosin (Figure3). The material was paucicellular, with some degenerated and afew typical Gaucher cells. The entire vitrectomy specimen was sent for centrifugationand analyzed via thin-layer chromatography, which showed a large amount ofglucosylceramide (Figure 4).

Place holder to copy figure label and caption
Figure 3.

Vitreous aspirate showing a Gauchercell (hematoxylin-eosin, original magnification ×250).

Graphic Jump Location
Place holder to copy figure label and caption
Figure 4.

Thin-layer chromatography of lipidsfrom vitreous and control lipids. Phospholipids were removed by alkaline methanolysis,dried under nitrogen gas, and resolved on borate-impregnated silica gel plates.Note intense staining of the glucosylceramide band in the patient.

Graphic Jump Location

Postoperative photographs of the operated-on eye showed a few remainingpreretinal white dots studding the retina and around the optic nerve head.A macular pucker was evident (Figure 5).Visual acuity was 20/40 at 6 months of follow-up.

Place holder to copy figure label and caption
Figure 5.

Color fundus photograph obtained6 months postoperatively. A few preretinal white dots stud the retina andoptic nerve. A macular pucker is evident.

Graphic Jump Location

Gaucher disease often occurs in Ashkenazi Jews but is panethnic.2 Type 1 Gaucher disease is characterized by an absenceof central nervous system involvement, in contrast to types 2 and 3, whichhave primary central nervous system disease. Classic descriptions of thisdisease mention multiple ocular and neurologic associations, such as conjunctivalpterygia, strabismus, and trismus with retroflexion of the neck. Vitreousopacities in this disorder were first noted by Cogan et al3 andGass.4 The incidence of vitreous opacitieswas found to be approximately 3% in a series of 80 consecutive patients withtype 1 Gaucher disease.5 Only those whohave undergone splenectomy have a tendency to form vitreous aggregates. Perhapsthis is due to the occurrence of more circulating glucosylceramide in thesepatients, resulting in manifestations in unusual systemic locations, suchas the eye. Our case is, to our knowledge, both the most severe that has beenreported and the first noting retinal vascular tortuosity. The corkscrew vascularpattern is reminiscent of that in Fabry disease, a related disorder of sphingolipidmetabolism. In our case, there were Gaucher cells in the vitreous cavity,while the vitreous gel contained large amounts of glucosylceramide.

The pathophysiologic mechanism of glucosylceramide deposition in thevitreous cavity is unclear. The material is a by-product of breakdown of myelin,leukocytes, red blood cells, and endothelial cells; myelin may be depositedwithin the eye when oligodendroglial cells migrate through the lamina cribrosa.Alternatively, deposition may occur by leakage from the vasculature. The latteris less likely, as glucosylceramide is not deposited within neurons in type1 Gaucher disease, although Gaucher cells do accumulate in the periadventitialmacrophages of the brain.1

We have shown that vision may be improved with vitrectomy in patientswith Gaucher disease. It is unknown whether vitreal opacities will recur inour patient, as has been reported in patients who have undergone vitrectomyfor vitreous opacities in familial amyloidotic polyneuropathy syndrome.6 The relationship of long-term enzyme replacementtherapy to the vitreous opacities in our patient is speculative.

The authors have no relevant financial interest in this article.

This study was supported by the Kentucky Lions Eye Foundation, Louisville,and in part by a grant from Research to Prevent Blindness Inc, New York, NY.

Correspondence: Dr Barr, Department of Ophthalmology and Visual Sciences,University of Louisville School of Medicine, 301 E Muhammad Ali Blvd, Louisville,KY 40202 (ccbarr@pol.net).

Beutler  EGrabowski  GA Glucosylceramide lipidosis: Gaucher disease. Scriver  CRSly  WSeds.The Metabolic andMolecular Bases of Inherited Disease. 8thed. New York, NY McGraw-HillBook Co2001;3635- 3668
Grabowski  GALeslie  NWenstrup  RW Enzyme therapy in Gaucher disease: the first 5 years. Blood Rev. 1998;12115- 133
PubMed
Cogan  DGChu  FCGittinger  JTychsen  L Fundal abnormalities of Gaucher's disease. Arch Ophthalmol. 1980;982202- 2203
PubMed
Gass  JDM Stereoscopic Atlas of Macular Disease and Treatment.  St Louis, Mo CV Mosby1997;408- 409
Wollstein  GElstein  DStrassman  ISeelenfreund  MZylbermann  RZimran  A Preretinal white dots in adult-type Gaucher disease. Retina. 1999;19570- 571
PubMed
Koga  TAndo  EHirata  A  et al.  Vitreous opacities and outcome of vitreous surgery in patients withfamilial amyloidotic polyneuropathy. Am J Ophthalmol. 2003;135188- 193
PubMed

Figures

Place holder to copy figure label and caption
Figure 1.

Fundus photographs of both eyesshowing prominent vitreous opacities.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Fluorescein angiograms of botheyes in transit phase showing blockage of fluorescence caused by vitreal opacities,and vascular tortuosity.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 3.

Vitreous aspirate showing a Gauchercell (hematoxylin-eosin, original magnification ×250).

Graphic Jump Location
Place holder to copy figure label and caption
Figure 4.

Thin-layer chromatography of lipidsfrom vitreous and control lipids. Phospholipids were removed by alkaline methanolysis,dried under nitrogen gas, and resolved on borate-impregnated silica gel plates.Note intense staining of the glucosylceramide band in the patient.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 5.

Color fundus photograph obtained6 months postoperatively. A few preretinal white dots stud the retina andoptic nerve. A macular pucker is evident.

Graphic Jump Location

Tables

References

Beutler  EGrabowski  GA Glucosylceramide lipidosis: Gaucher disease. Scriver  CRSly  WSeds.The Metabolic andMolecular Bases of Inherited Disease. 8thed. New York, NY McGraw-HillBook Co2001;3635- 3668
Grabowski  GALeslie  NWenstrup  RW Enzyme therapy in Gaucher disease: the first 5 years. Blood Rev. 1998;12115- 133
PubMed
Cogan  DGChu  FCGittinger  JTychsen  L Fundal abnormalities of Gaucher's disease. Arch Ophthalmol. 1980;982202- 2203
PubMed
Gass  JDM Stereoscopic Atlas of Macular Disease and Treatment.  St Louis, Mo CV Mosby1997;408- 409
Wollstein  GElstein  DStrassman  ISeelenfreund  MZylbermann  RZimran  A Preretinal white dots in adult-type Gaucher disease. Retina. 1999;19570- 571
PubMed
Koga  TAndo  EHirata  A  et al.  Vitreous opacities and outcome of vitreous surgery in patients withfamilial amyloidotic polyneuropathy. Am J Ophthalmol. 2003;135188- 193
PubMed

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles